Press release
Hypertriglyceridemia Clinical, Companies, Therapy Assessment, Therapies, Pipeline| NorthSea Therapeutics, Arrowhead Pharmaceuticals, Zhejiang Doer Biologics, Ionis Pharmaceuticals, GeneCradle, MediciN
Hypertriglyceridemia Clinical Trials
DelveInsight's analysis reveals that the Hypertriglyceridemia pipeline includes over 18 leading companies actively engaged in developing 20+ therapeutic candidates. The comprehensive report covers the clinical landscape, company profiles, therapeutic assessments, treatment algorithms, and pipeline insights, featuring key players such as NorthSea Therapeutics, Arrowhead Pharmaceuticals, Zhejiang Doer Biologics, Ionis Pharmaceuticals, GeneCradle, MediciNova, and Regeneron Pharmaceuticals.
Hypertriglyceridemia Overview:
Hypertriglyceridemia is characterized by elevated triglyceride levels in the bloodstream, often associated with an increased risk of cardiovascular disease (CVD) and acute pancreatitis. The condition typically develops due to uncontrolled diabetes, obesity, sedentary lifestyle, or genetic predispositions. Most individuals remain asymptomatic until triglyceride levels rise above 1000-2000 mg/dL, at which point serious complications such as pancreatitis and metabolic disturbances may occur. Management primarily involves lifestyle interventions-including a balanced diet, weight reduction, and regular physical activity-supplemented with pharmacologic options like statins or fibrates when necessary. Addressing underlying risk factors is key to minimizing overall health complications.
Although often without noticeable symptoms, very high triglyceride levels (above 500 mg/dL) markedly increase the risk of acute pancreatitis, which may manifest as severe abdominal pain, nausea, and vomiting. In familial or genetic cases, xanthomas-yellowish fatty deposits around the eyes, elbows, or knees-can occur. Other, less common manifestations include hepatosplenomegaly (enlarged liver and spleen) and lipemia retinalis, a retinal condition affecting vision. Despite its often silent nature, hypertriglyceridemia reflects deeper metabolic dysfunction and substantially raises the risk of cardiovascular complications.
Request for a detailed insights report on Hypertriglyceridemia pipeline insights [https://www.delveinsight.com/report-store/hypertriglyceridemia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Hypertriglyceridemia Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hypertriglyceridemia Therapeutics Market.
Key Takeaways from the Hypertriglyceridemia Pipeline Report
*
DelveInsight's Hypertriglyceridemia Pipeline Report highlights a dynamic landscape, featuring over 18 active companies developing more than 20 investigational therapies aimed at treating Hypertriglyceridemia.
*
In September 2025, Ionis Pharmaceuticals' experimental drug olezarsen (already approved under the brand name Tryngolza for Familial Chylomicronemia Syndrome (FCS)) showed very strong Phase III data in severe hypertriglyceridemia (sHTG) patients: up to ~72% reduction in triglycerides and ~85% reduction in pancreatitis events compared to placebo.
*
In December 2024, the FDA approved Tryngolza Registered (olezarsen)-an injectable antisense oligonucleotide targeting apoC-III-as an adjunct to dietary management for adults with familial chylomicronemia syndrome (FCS), marking it as the first FDA-approved therapy for this rare condition.
*
Leading companies such as NorthSea Therapeutics, Arrowhead Pharmaceuticals, Zhejiang Doer Biologics, Ionis Pharmaceuticals, GeneCradle, MediciNova, and Regeneron Pharmaceuticals are actively advancing novel candidates to enhance the Hypertriglyceridemia treatment landscape.
*
Prominent pipeline therapies currently in development include SEFA-1024, DR10624, GC304, and several others showing strong potential across various clinical stages.
Hypertriglyceridemia Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Hypertriglyceridemia Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypertriglyceridemia treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hypertriglyceridemia market.
Download our free sample page report on Hypertriglyceridemia pipeline insights [https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Hypertriglyceridemia Emerging Drugs
SEFA-1024 - NorthSea Therapeutics
SEFA-1024 is an oral, semi-synthetic derivative of eicosapentaenoic acid engineered to act primarily on the gut and liver. It is under development for severe hypertriglyceridemia (sHTG)-a condition associated with an increased risk of acute pancreatitis and potentially cardiovascular disease.
Existing therapies often fail to adequately control triglycerides (TG), non-HDL cholesterol, and glucose levels, highlighting a substantial unmet medical need. Backed by strong preclinical results in a human hypertriglyceridemia model, SEFA-1024 demonstrates encouraging potential to fill this therapeutic gap. The candidate is currently being evaluated in Phase II clinical trials for hypertriglyceridemia.
DR10624 - Doer Biologics
DR10624 is a first-in-class, long-acting tri-agonist that concurrently activates FGF21R, GLP-1R, and the glucagon receptor (GCGR). Developed using Doer Biologics' proprietary MultipleBody platform, it is designed to deliver balanced therapeutic effects across several key metabolic pathways.
Preclinical studies have demonstrated that DR10624 can substantially reduce body weight, lower triglyceride levels, improve overall lipid profiles, and support liver function. The candidate is currently in Phase II clinical trials for the treatment of severe hypertriglyceridemia (sHTG).
Hypertriglyceridemia Companies
Approximately 18 or more leading companies are actively engaged in developing therapies for Hypertriglyceridemia. Among these, NorthSea Therapeutics stands out, with its drug candidate progressing to the most advanced development stage-Phase II clinical trials.
DelveInsight's report covers around 75+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Hypertriglyceridemia Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Hypertriglyceridemia Therapies and Key Companies: Hypertriglyceridemia Clinical Trials and advancements [https://www.delveinsight.com/report-store/hypertriglyceridemia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Hypertriglyceridemia Pipeline Therapeutic Assessment
- Hypertriglyceridemia Assessment by Product Type
- Hypertriglyceridemia By Stage
- Hypertriglyceridemia Assessment by Route of Administration
- Hypertriglyceridemia Assessment by Molecule Type
Download Hypertriglyceridemia Sample report to know in detail about the Hypertriglyceridemia treatment market @ Hypertriglyceridemia Therapeutic Assessment [https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Hypertriglyceridemia Current Treatment Patterns
4. Hypertriglyceridemia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Hypertriglyceridemia Late-Stage Products (Phase-III)
7. Hypertriglyceridemia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hypertriglyceridemia Discontinued Products
13. Hypertriglyceridemia Product Profiles
14. Hypertriglyceridemia Key Companies
15. Hypertriglyceridemia Key Products
16. Dormant and Discontinued Products
17. Hypertriglyceridemia Unmet Needs
18. Hypertriglyceridemia Future Perspectives
19. Hypertriglyceridemia Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Hypertriglyceridemia Pipeline Reports Offerings [https://www.delveinsight.com/report-store/hypertriglyceridemia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypertriglyceridemia-clinical-companies-therapy-assessment-therapies-pipeline-northsea-therapeutics-arrowhead-pharmaceuticals-zhejiang-doer-biologics-ionis-pharmaceuticals-genecradle-medicin]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypertriglyceridemia Clinical, Companies, Therapy Assessment, Therapies, Pipeline| NorthSea Therapeutics, Arrowhead Pharmaceuticals, Zhejiang Doer Biologics, Ionis Pharmaceuticals, GeneCradle, MediciN here
News-ID: 4241450 • Views: …
More Releases from ABNewswire
Native Hawaiian Veteran-Founded Day Job Flex Launches Apparel Celebrating Nurses …
Day Job Flex, a Native Hawaiian, veteran-founded, woman-co-led family business, is creating apparel that honors hard working professionals-starting with nurses-by celebrating both their careers and the passions that define them beyond their day jobs. The company's authentic, community-driven approach stems from experience printing for local businesses, schools and organizations, now expanded to serve professionals whose voices rarely appear in mainstream apparel.
A new apparel brand is challenging the convention that professional…
Father-Son Duo Launches PlayQuest to Bridge the Family Board Game Gap with Award …
PlayQuest LLC, a family-owned board game company founded in 2022, is revolutionizing family game night with educational games designed for children ages 5 and up that adults actually enjoy playing. The company's innovative five-point pledge ensures every game enhances critical skills while delivering engaging gameplay that brings generations together around the table.
A new player has entered the family board game market with a mission to transform game night from a…
From The Farm Candles Launches with Commitment to Natural Ingredients and Sustai …
From The Farm Candles brings farm-fresh authenticity to the home fragrance market with handcrafted candles made exclusively from natural ingredients and premium soy wax. The new venture prioritizes environmental responsibility through recyclable packaging and minimalist production methods that reduce carbon footprint while delivering affordable luxury to candle enthusiasts seeking clean-burning alternatives to mass-produced home fragrance products.
From The Farm Candles has entered the home fragrance market with a refreshing approach that…
Whimsical Keepsakes Launches Handcrafted Memory Collection Just in Time for Holi …
Whimsical Keepsakes, LLC introduces a heartfelt alternative to mass-produced holiday gifts with their collection of personalized, handcrafted keepsakes. The husband-and-wife owned company transforms cherished memories into tangible art, offering everything from woven blankets to engraved jewelry, with 10% of select collections benefiting the Make-A-Wish Foundation.
As holiday shopping season begins, a new company is offering gift-givers an alternative to generic presents that end up in donation boxes. Whimsical Keepsakes, LLC has…
More Releases for Hypertriglyceridemia
Hypertriglyceridemia Market is expected to reach USD 39 billion by 2034
Hypertriglyceridemia is a common lipid disorder characterized by elevated levels of triglycerides in the blood, often associated with obesity, diabetes, metabolic syndrome, and genetic predisposition. While mild to moderate hypertriglyceridemia is widespread, severe cases can lead to acute pancreatitis, cardiovascular disease, and liver complications. The condition is both a standalone metabolic issue and a risk factor for a broader spectrum of chronic diseases.
Download Full PDF Sample Copy of Market Report…
Severe Hypertriglyceridemia Market is expected to reach USD 8.9 billion by 2034
Severe hypertriglyceridemia, defined by triglyceride levels exceeding 500 mg/dL, is a serious metabolic condition linked to an elevated risk of cardiovascular disease, pancreatitis, and liver complications. As obesity, sedentary lifestyles, and diabetes become more prevalent worldwide, the burden of hypertriglyceridemia is rising rapidly. This has created a significant demand for effective pharmacological treatments, dietary interventions, and lifestyle management solutions.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72003
According to Exactitude…
Severe Hypertriglyceridemia Treatment Drugs, Pipeline Insights, Emerging Therapi …
DelveInsight's, "Severe Hypertriglyceridemia Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Severe Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Severe…
Hypertriglyceridemia Therapeutics Market Detailed In New Research Report 2024 |S …
The most recent report published by CMI indicates that the "Hypertriglyceridemia Therapeutics Market 2024-2031" is likely to accelerate significantly in the next few years. The Hypertriglyceridemia Therapeutics Market report gives a purposeful depiction of the area by the practice for research, amalgamation, market size, overview, and review of data taken from various sources. The Hypertriglyceridemia Therapeutics Market study includes information on market factors such as the market dynamics, drivers, restraints,…
Navigating Hypertriglyceridemia: Causes, Risks, and Effective Management Strateg …
Hypertriglyceridemia is a common disorder or condition wherein the triglyceride levels in the blood are higher. The growing triglyceride levels are mostly associated with atherosclerosis and cardiovascular diseases (CVDs). This condition also causes pancreatitis, atherosclerosis, and other CVDs. Hypertriglyceridemia is generally worsened or caused by numerous factors such as sedentary lifestyle, poorly controlled diabetes, and obesity. Corneal arcus, xanthelasmas, memory loss, difficulty breathing, dementia, and gastrointestinal pain are typical symptoms…
Hypertriglyceridemia: Unraveling the Highs and Lows of Triglyceride Metabolism
Hypertriglyceridemia is a common disorder or condition wherein the triglyceride levels in the blood are higher. The growing triglyceride levels are mostly associated with atherosclerosis and cardiovascular diseases (CVDs). This condition also causes pancreatitis, atherosclerosis, and other CVDs. Hypertriglyceridemia is generally worsened or caused by numerous factors such as sedentary lifestyle, poorly controlled diabetes, and obesity. Corneal arcus, xanthelasmas, memory loss, difficulty breathing, dementia, and gastrointestinal pain are typical symptoms…
